Whitehawk Therapeutics, Inc. announced its financial results for the fiscal year ended December 31, 2025, highlighting a cash balance of $145.7 million, expected to fund operations into 2028. The company is actively recruiting for Phase 1 trials of its ADC candidates HWK-007 and HWK-016.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.